Literature DB >> 10419901

Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia.

G Gruber1, J D Schwarzmeier, M Shehata, M Hilgarth, R Berger.   

Abstract

Several features are characteristic for hairy cell leukemia (HCL). Among those are pancytopenia, bone marrow fibrosis, and the appearance of a defined tumor cell phenotype in peripheral blood (PB), bone marrow (BM), and spleen. Hairy cells (HC) coexpress antigens specific for B lymphocytes and monocytes/macrophages and thus the malignant cell does not seem to be restricted to a defined lineage. When serum or bone marrow aspirate was screened by enzyme-linked immunosorbent assay (ELISA) for basic fibroblast growth factor (bFGF), specimen derived from HCL (serum: mean value, 29 pg/mL; BM aspirate: mean value, 641 pg/mL) contained significantly higher levels than those from healthy subjects. To study whether peripheral blood mononuclear cells (PBMC) derived from patients suffering from HCL and healthy donors (HD) were capable of producing bFGF, culture supernatant (conditioned medium, [CM]) was tested for the presence of this cytokine. While bFGF was not detectable in cell cultures from HD, HCL-derived CM contained relatively high levels of bFGF. CM was successfully used for stimulation of mesenchymal cell proliferation, which could be inhibited by a neutralizing anti-bFGF antibody. Cellular activation by pokeweed mitogen (PWM) or the combination of 12-o-tetradecanoyl-phorbol-13-acetate (TPA) plus calcium ionophore (Ca-Ip) led to an enhanced mRNA expression. Results of Western blot experiments showed that HC synthesize at least three isoforms (approximately 18, 23, and 25 kD), but only the 23-kD isoform is exported. To assess the nature of the producer cell, double immunofluorescence analysis using a bFGF-specific and an anti-CD11c monoclonal antibody (MoAb) was undertaken. The majority of cells scoring positive for CD11c were also reactive with the anti-bFGF MoAb. Furthermore, enrichment of CD19/CD11c-positive cells correlated with enhanced bFGF levels, thereby supporting the argument for HC being the producer cells of bFGF. A biological function of bFGF in HCL might be mediation of chemoresistance, as 2-chlorodeoxyadenosine (2-CdA)-induced inhibition of cell proliferation can be reversed by bFGF. Endogenous bFGF production by HC is not affected by this purine analogue and 2-CdA-induced apoptosis is diminished in bFGF-producing HC as compared with normal PBMC. Therefore, bFGF expression by HC might be important for resistance to chemotherapy and survival of the malignant cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419901

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer.

Authors:  Ana Sahores; Virginia Figueroa; María May; Marcos Liguori; Adrián Rubstein; Cynthia Fuentes; Britta M Jacobsen; Andrés Elía; Paola Rojas; Gonzalo R Sequeira; Michelle M Álvarez; Pedro González; Hugo Gass; Stephen Hewitt; Alfredo Molinolo; Claudia Lanari; Caroline A Lamb
Journal:  Horm Cancer       Date:  2018-06-28       Impact factor: 3.869

Review 2.  High molecular weight FGF2: the biology of a nuclear growth factor.

Authors:  K Chlebova; V Bryja; P Dvorak; A Kozubik; W R Wilcox; P Krejci
Journal:  Cell Mol Life Sci       Date:  2009-01       Impact factor: 9.261

Review 3.  Update on the biology and treatment options for hairy cell leukemia.

Authors:  Preetesh Jain; Naveen Pemmaraju; Farhad Ravandi
Journal:  Curr Treat Options Oncol       Date:  2014-06

4.  TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia.

Authors:  Medhat Shehata; Josef D Schwarzmeier; Martin Hilgarth; Rainer Hubmann; Markus Duechler; Heinz Gisslinger
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

5.  Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors.

Authors:  Katia Basso; Arcangelo Liso; Enrico Tiacci; Roberta Benedetti; Alessandro Pulsoni; Robin Foa; Francesco Di Raimondo; Achille Ambrosetti; Andrea Califano; Ulf Klein; Riccardo Dalla Favera; Brunangelo Falini
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307

6.  Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma.

Authors:  I Pazgal; Y Zimra; C Tzabar; E Okon; E Rabizadeh; M Shaklai; O Bairey
Journal:  Br J Cancer       Date:  2002-06-05       Impact factor: 7.640

Review 7.  Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Betty Tai; Sathyen A Prabhu; Catherine M Capac; Matthew Gliksman; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.